Skip to main content

Table 3 Association of TG/HDL-C ratio with the absolute change, change rate and slope of baPWV

From: Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population

  Model 1 Model 2 Model 3
β 95% CI P value β 95% CI P value β 95% CI P value
Change of baPWV (cm/s)
 TG/HDL-C ratio (continuous) 6.795 − 1.193 to 14.784 0.096 4.934 − 3.684 to 13.552 0.062 37.057 7.85–66.264 0.013
 Quartile 2 (ref: quartile 1) 70.320 21.037–119.604 0.005 68.883 19.964–117.802 0.006 75.317 24.101–126.534 0.004
 Quartile 3 83.153 34.299–132.007 0.001 89.453 38.544–140.362 0.001 84.036 25.516–142.556 0.005
 Quartile 4 131.912 82.542–181.282 < 0.001 142.938 78.525–207.35 < 0.001 133.420 51.949–214.891 0.001
 P for trend    < 0.001    < 0.001    0.002
Change rate of baPWV (cm/s/year)
 TG/HDL-C ratio (continuous) 2.587 0.115–5.06 0.040 1.880 − 0.801 to 4.562 0.169 9.768 0.547–18.989 0.038
 Quartile 2 (ref: quartile 1) 14.121 − 1.149 to 29.392 0.070 13.621 − 1.616 to 28.857 0.080 19.486 3.325–35.646 0.018
 Quartile 3 23.979 8.842–39.117 0.002 25.543 9.687–41.399 0.002 29.615 11.15–48.08 0.002
 Quartile 4 38.237 22.94–53.534 < 0.001 40.369 20.307–60.431 < 0.001 43.511 17.804–69.217 0.001
 P for trend    < 0.001    < 0.001    0.001
Slope of baPWV
 TG/HDL-C ratio (continuous) 2.253 − 0.089 to 4.595 0.060 4.507 1.425–6.048 0.045 7.973 0.801–22.317 0.035
 Quartile 2 (ref: quartile 1) 12.212 − 2.264 to 26.687 0.098 11.300 − 3.154 to 25.754 0.126 15.465 0.078–30.852 0.049
 Quartile 3 21.636 7.287–35.986 0.003 21.977 6.935–37.019 0.004 24.296 6.715–41.877 0.007
 Quartile 4 33.088 18.587–47.589 < 0.001 32.178 13.146–51.21 0.001 33.496 9.02–57.972 0.007
 P for trend    < 0.001    < 0.001    0.004
  1. Model 1: adjusted age and sex; Model 2: age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at baseline and follow-up; Model 3: Model 2 plus HDL-C, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up